Literature DB >> 16619239

Long-range PCR facilitates the identification of PMS2-specific mutations.

Mark Clendenning1, Heather Hampel, Jennifer LaJeunesse, Annika Lindblom, Jan Lockman, Mef Nilbert, Leigha Senter, Kaisa Sotamaa, Albert de la Chapelle.   

Abstract

Mutations within the DNA mismatch repair gene, "postmeiotic segregation increased 2" (PMS2), have been associated with a predisposition to hereditary nonpolyposis colorectal cancer (HNPCC; Lynch syndrome). The presence of a large family of highly homologous PMS2 pseudogenes has made previous attempts to sequence PMS2 very difficult. Here, we describe a novel method that utilizes long-range PCR as a way to preferentially amplify PMS2 and not the pseudogenes. A second, exon-specific, amplification from diluted long-range products enables us to obtain a clean sequence that shows no evidence of pseudogene contamination. This method has been used to screen a cohort of patients whose tumors were negative for the PMS2 protein by immunohistochemistry and had not shown any mutations within the MLH1 gene. Sequencing of the PMS2 gene from 30 colorectal and 11 endometrial cancer patients identified 10 novel sequence changes as well as 17 sequence changes that had previously been identified. In total, putative pathologic mutations were detected in 11 of the 41 families. Among these were five novel mutations, c.705+1G>T, c.736_741del6ins11, c.862_863del, c.1688G>T, and c.2007-1G>A. We conclude that PMS2 mutation detection in selected Lynch syndrome and Lynch syndrome-like patients is both feasible and desirable. Published 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619239     DOI: 10.1002/humu.20318

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  43 in total

1.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

2.  Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene.

Authors:  Mark Drost; Hester Koppejan; Niels de Wind
Journal:  Hum Mutat       Date:  2013-09-11       Impact factor: 4.878

3.  The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.

Authors:  Britta Halvarsson; Annika Lindblom; Eva Rambech; Kristina Lagerstedt; Mef Nilbert
Journal:  Fam Cancer       Date:  2006-07-12       Impact factor: 2.375

4.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer.

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

5.  Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog.

Authors:  Daniel S Herman; Christina Smith; Chang Liu; Cecily P Vaughn; Selvi Palaniappan; Colin C Pritchard; Brian H Shirts
Journal:  J Mol Diagn       Date:  2018-05-22       Impact factor: 5.568

6.  Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer.

Authors:  Rhiannon J Walters; Elizabeth J Williamson; Dallas R English; Joanne P Young; Christophe Rosty; Mark Clendenning; Michael D Walsh; Susan Parry; Dennis J Ahnen; John A Baron; Aung Ko Win; Graham G Giles; John L Hopper; Mark A Jenkins; Daniel D Buchanan
Journal:  Epigenetics       Date:  2013-06-17       Impact factor: 4.528

7.  The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease.

Authors:  M O Woods; H B Younghusband; P S Parfrey; S Gallinger; J McLaughlin; E Dicks; S Stuckless; A Pollett; B Bapat; M Mrkonjic; A de la Chapelle; M Clendenning; S N Thibodeau; M Simms; A Dohey; P Williams; D Robb; C Searle; J S Green; R C Green
Journal:  Gut       Date:  2010-08-03       Impact factor: 23.059

8.  Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.

Authors:  Sridharan Gururangan; Wendy Frankel; Russell Broaddus; Mark Clendenning; Leigha Senter; Marie McDonald; James Eastwood; David Reardon; James Vredenburgh; Jennifer Quinn; Henry S Friedman
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

9.  Detection of large scale 3' deletions in the PMS2 gene amongst Colon-CFR participants: have we been missing anything?

Authors:  Mark Clendenning; Michael D Walsh; Judith Balmana Gelpi; Stephen N Thibodeau; Noralane Lindor; John D Potter; Polly Newcomb; Loic LeMarchand; Robert Haile; Steve Gallinger; John L Hopper; Mark A Jenkins; Christophe Rosty; Joanne P Young; Daniel D Buchanan
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

10.  Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.

Authors:  Israel Zighelboim; Matthew A Powell; Sheri A Babb; Alison J Whelan; Amy P Schmidt; Mark Clendenning; Leigha Senter; Stephen N Thibodeau; Albert de la Chapelle; Paul J Goodfellow
Journal:  Fam Cancer       Date:  2009-08-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.